Laura Chico
Stock Analyst at Wedbush
(3.94)
# 614
Out of 5,182 analysts
264
Total ratings
46.81%
Success rate
11.66%
Average return
Main Sectors:
Stocks Rated by Laura Chico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Reiterates: Outperform | $7 | $2.70 | +159.26% | 4 | Apr 15, 2026 | |
| TVTX Travere Therapeutics | Maintains: Outperform | $39 → $44 | $40.89 | +7.61% | 13 | Apr 14, 2026 | |
| VRDN Viridian Therapeutics | Maintains: Outperform | $37 → $31 | $13.61 | +127.77% | 11 | Apr 8, 2026 | |
| NBIX Neurocrine Biosciences | Maintains: Outperform | $151 → $166 | $128.12 | +29.57% | 12 | Apr 7, 2026 | |
| PHVS Pharvaris | Maintains: Outperform | $41 → $42 | $28.22 | +48.83% | 9 | Apr 7, 2026 | |
| ANRO Alto Neuroscience | Maintains: Neutral | $22 → $21 | $24.47 | -14.18% | 6 | Apr 2, 2026 | |
| PEPG PepGen | Maintains: Outperform | $9 → $5 | $1.58 | +216.46% | 14 | Apr 1, 2026 | |
| LRMR Larimar Therapeutics | Maintains: Outperform | $12 → $13 | $4.40 | +195.45% | 6 | Mar 20, 2026 | |
| STOK Stoke Therapeutics | Maintains: Outperform | $36 → $38 | $33.33 | +14.01% | 11 | Mar 18, 2026 | |
| EWTX Edgewise Therapeutics | Reiterates: Outperform | $32 | $30.99 | +3.26% | 12 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $64 → $63 | $54.53 | +15.53% | 11 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $43 → $58 | $25.82 | +124.63% | 3 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $17 | $7.45 | +128.19% | 5 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $103 | $83.67 | +23.10% | 14 | Mar 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $24 | $26.46 | -9.28% | 4 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $14 | $9.26 | +51.19% | 2 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $20 → $18 | $40.99 | -56.09% | 15 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $6 → $1 | $0.34 | +189.94% | 7 | Feb 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $19 | $5.97 | +218.26% | 16 | Feb 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $95 → $130 | $321.92 | -59.62% | 12 | Feb 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $25 | $24.53 | +1.92% | 15 | Feb 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $178 → $187 | $183.38 | +1.97% | 20 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $30 | $20.06 | +49.55% | 10 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $23 → $33 | $37.11 | -11.08% | 9 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $18 | $8.86 | +103.16% | 1 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $8 → $7 | $3.77 | +85.68% | 4 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $104 → $88 | $8.80 | +900.00% | 4 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $12.81 | -60.97% | 5 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $53.30 | - | 5 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $6.30 | -20.63% | 2 | Aug 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $149 | $9.61 | +1,445.27% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $720 | $9.82 | +7,231.98% | 1 | Jan 19, 2018 |
Ovid Therapeutics
Apr 15, 2026
Reiterates: Outperform
Price Target: $7
Current: $2.70
Upside: +159.26%
Travere Therapeutics
Apr 14, 2026
Maintains: Outperform
Price Target: $39 → $44
Current: $40.89
Upside: +7.61%
Viridian Therapeutics
Apr 8, 2026
Maintains: Outperform
Price Target: $37 → $31
Current: $13.61
Upside: +127.77%
Neurocrine Biosciences
Apr 7, 2026
Maintains: Outperform
Price Target: $151 → $166
Current: $128.12
Upside: +29.57%
Pharvaris
Apr 7, 2026
Maintains: Outperform
Price Target: $41 → $42
Current: $28.22
Upside: +48.83%
Alto Neuroscience
Apr 2, 2026
Maintains: Neutral
Price Target: $22 → $21
Current: $24.47
Upside: -14.18%
PepGen
Apr 1, 2026
Maintains: Outperform
Price Target: $9 → $5
Current: $1.58
Upside: +216.46%
Larimar Therapeutics
Mar 20, 2026
Maintains: Outperform
Price Target: $12 → $13
Current: $4.40
Upside: +195.45%
Stoke Therapeutics
Mar 18, 2026
Maintains: Outperform
Price Target: $36 → $38
Current: $33.33
Upside: +14.01%
Edgewise Therapeutics
Mar 17, 2026
Reiterates: Outperform
Price Target: $32
Current: $30.99
Upside: +3.26%
Mar 16, 2026
Maintains: Outperform
Price Target: $64 → $63
Current: $54.53
Upside: +15.53%
Mar 16, 2026
Maintains: Outperform
Price Target: $43 → $58
Current: $25.82
Upside: +124.63%
Mar 12, 2026
Maintains: Outperform
Price Target: $14 → $17
Current: $7.45
Upside: +128.19%
Mar 12, 2026
Maintains: Outperform
Price Target: $80 → $103
Current: $83.67
Upside: +23.10%
Mar 9, 2026
Reiterates: Outperform
Price Target: $24
Current: $26.46
Upside: -9.28%
Mar 6, 2026
Maintains: Outperform
Price Target: $12 → $14
Current: $9.26
Upside: +51.19%
Feb 25, 2026
Maintains: Neutral
Price Target: $20 → $18
Current: $40.99
Upside: -56.09%
Feb 24, 2026
Downgrades: Neutral
Price Target: $6 → $1
Current: $0.34
Upside: +189.94%
Feb 23, 2026
Reiterates: Outperform
Price Target: $19
Current: $5.97
Upside: +218.26%
Feb 20, 2026
Maintains: Underperform
Price Target: $95 → $130
Current: $321.92
Upside: -59.62%
Feb 17, 2026
Reiterates: Neutral
Price Target: $25
Current: $24.53
Upside: +1.92%
Feb 10, 2026
Maintains: Neutral
Price Target: $178 → $187
Current: $183.38
Upside: +1.97%
Dec 11, 2025
Maintains: Outperform
Price Target: $31 → $30
Current: $20.06
Upside: +49.55%
Dec 11, 2025
Maintains: Neutral
Price Target: $23 → $33
Current: $37.11
Upside: -11.08%
Jun 30, 2025
Maintains: Outperform
Price Target: $16 → $18
Current: $8.86
Upside: +103.16%
Aug 7, 2024
Maintains: Neutral
Price Target: $8 → $7
Current: $3.77
Upside: +85.68%
Apr 11, 2024
Maintains: Outperform
Price Target: $104 → $88
Current: $8.80
Upside: +900.00%
Mar 20, 2024
Reiterates: Neutral
Price Target: $5
Current: $12.81
Upside: -60.97%
Sep 28, 2023
Initiates: Market Perform
Price Target: n/a
Current: $53.30
Upside: -
Aug 12, 2022
Maintains: Outperform
Price Target: $9 → $5
Current: $6.30
Upside: -20.63%
Aug 8, 2022
Downgrades: Neutral
Price Target: $149
Current: $9.61
Upside: +1,445.27%
Jan 19, 2018
Initiates: Outperform
Price Target: $720
Current: $9.82
Upside: +7,231.98%